22nd Century Group Inc (NYSEAMERICAN:XXII) Director Purchases $17,160.00 in Stock

22nd Century Group Inc (NYSEAMERICAN:XXII) Director Nora B. Sullivan purchased 22,000 shares of the business’s stock in a transaction on Monday, June 29th. The stock was acquired at an average cost of $0.78 per share, with a total value of $17,160.00. Following the completion of the acquisition, the director now directly owns 308,523 shares in the company, valued at approximately $240,647.94. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of XXII opened at $0.78 on Wednesday. 22nd Century Group Inc has a 12-month low of $0.60 and a 12-month high of $2.46.

22nd Century Group (NYSEAMERICAN:XXII) last released its earnings results on Thursday, May 7th. The biotechnology company reported ($0.03) EPS for the quarter. The company had revenue of $7.10 million for the quarter.

Several large investors have recently made changes to their positions in XXII. Advisor Group Holdings Inc. purchased a new stake in shares of 22nd Century Group during the first quarter valued at $145,000. Squarepoint Ops LLC acquired a new stake in 22nd Century Group during the 1st quarter worth about $151,000. Geode Capital Management LLC lifted its stake in 22nd Century Group by 8.0% during the first quarter. Geode Capital Management LLC now owns 1,632,375 shares of the biotechnology company’s stock valued at $1,223,000 after buying an additional 121,416 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in shares of 22nd Century Group by 87.1% in the first quarter. Alliancebernstein L.P. now owns 122,000 shares of the biotechnology company’s stock worth $92,000 after buying an additional 56,800 shares during the period. Finally, ETF Managers Group LLC increased its position in shares of 22nd Century Group by 62.3% in the first quarter. ETF Managers Group LLC now owns 13,385,853 shares of the biotechnology company’s stock worth $10,039,000 after acquiring an additional 5,140,644 shares in the last quarter.

22nd Century Group Company Profile

22nd Century Group, Inc, a plant biotechnology company, provides technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. It offers premium cigarettes under the RED SUN and MAGIC brands; and SPECTRUM research cigarettes for use in independent clinical studies.

Further Reading: New Google Finance Tool and Screening Stocks

Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.